Harrow Reports Q4 Earnings

Pharmaceutical company's results miss Wall Street expectations

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

Harrow, Inc., a pharmaceutical and drug compounding company based in Nashville, Tennessee, reported fourth-quarter earnings of $6.6 million, or 17 cents per share. However, the results did not meet Wall Street expectations, as the average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 40 cents per share.

Why it matters

Harrow's financial performance is closely watched by investors and analysts as an indicator of the company's overall health and growth prospects within the pharmaceutical industry.

The details

Harrow reported revenue of $89.1 million in the fourth quarter, which beat Street forecasts. However, the company's earnings, adjusted for amortization costs, came to 26 cents per share, falling short of the 40 cents per share expected by analysts. For the full year, Harrow reported a loss of $5.1 million, or 14 cents per share, on revenue of $272.3 million.

  • Harrow reported its fourth-quarter earnings on Monday, March 2, 2026.

The players

Harrow, Inc.

A pharmaceutical and drug compounding company based in Nashville, Tennessee.

Got photos? Submit your photos here. ›

The takeaway

Harrow's mixed financial results in the fourth quarter highlight the challenges the pharmaceutical industry faces in meeting analyst expectations, even as the company continues to generate significant revenue.